Merck KGaA, Darmstadt, Germany announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation.....
Merck KGaA has announced new and updated results from expansion cohorts of two ongoing Phase I clinical trials (NCT02517398 and NCT02699515) for its immunotherapy M7824.